183 related articles for article (PubMed ID: 34944801)
1. HLA Class II Histocompatibility Antigen γ Chain (CD74) Expression Is Associated with Immune Cell Infiltration and Favorable Outcome in Breast Cancer.
Noer JB; Talman MM; Moreira JMA
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944801
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in triple-negative breast cancer.
Katz H; Alsharedi M
Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
[TBL] [Abstract][Full Text] [Related]
3. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
4. Progress and challenges of immunotherapy in triple-negative breast cancer.
Zhu Y; Zhu X; Tang C; Guan X; Zhang W
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188593. PubMed ID: 34280474
[TBL] [Abstract][Full Text] [Related]
5. Macrophage migration inhibitory factor-CD74 interaction regulates the expression of programmed cell death ligand 1 in melanoma cells.
Imaoka M; Tanese K; Masugi Y; Hayashi M; Sakamoto M
Cancer Sci; 2019 Jul; 110(7):2273-2283. PubMed ID: 31069878
[TBL] [Abstract][Full Text] [Related]
6. CD74 and intratumoral immune response in breast cancer.
Wang ZQ; Milne K; Webb JR; Watson PH
Oncotarget; 2017 Feb; 8(8):12664-12674. PubMed ID: 27058619
[TBL] [Abstract][Full Text] [Related]
7. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD74 in invasive breast carcinoma: its relation to Nottingham Prognostic Index, hormone receptors, and HER2 immunoprofile.
Hasby EA; Khalifa RA
Tumori; 2017 Mar; 103(2):193-203. PubMed ID: 27834468
[TBL] [Abstract][Full Text] [Related]
9. CD74: a potential novel target for triple-negative breast cancer.
Tian B; Zhang Y; Li N; Liu X; Dong J
Tumour Biol; 2012 Dec; 33(6):2273-7. PubMed ID: 22935920
[TBL] [Abstract][Full Text] [Related]
10. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
12. Cell-surface expression of human histocompatibility leucocyte antigen (HLA) class II-associated invariant chain (CD74) does not always correlate with cell-surface expression of HLA class II molecules.
Wilson KM; Labeta MO; Pawelec G; Fernandez N
Immunology; 1993 Jun; 79(2):331-5. PubMed ID: 8344710
[TBL] [Abstract][Full Text] [Related]
13. HLA-DR and CD74 Expression and the Immune Microenvironment in Renal Cell Carcinoma.
Miura Y; Anami T; Yatsuda J; Motoshima T; Oka S; Suyama K; Inoshita N; Kinowaki K; Urakami S; Kamba T; Komohara Y
Anticancer Res; 2021 Jun; 41(6):2841-2848. PubMed ID: 34083274
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
15. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.
Noske A; Möbus V; Weber K; Schmatloch S; Weichert W; Köhne CH; Solbach C; Ingold Heppner B; Steiger K; Müller V; Fasching P; Karn T; van Mackelenbergh M; Marmé F; Schmitt WD; Schem C; Stickeler E; Loibl S; Denkert C
Eur J Cancer; 2019 Jun; 114():76-88. PubMed ID: 31075727
[TBL] [Abstract][Full Text] [Related]
16. Triple-negative breast cancer and basal-like subtype : Pathology and targeted therapy.
Bando Y; Kobayashi T; Miyakami Y; Sumida S; Kakimoto T; Saijo Y; Uehara H
J Med Invest; 2021; 68(3.4):213-219. PubMed ID: 34759133
[TBL] [Abstract][Full Text] [Related]
17. Immunogenic Cell Death-Relevant Damage-Associated Molecular Patterns and Sensing Receptors in Triple-Negative Breast Cancer Molecular Subtypes and Implications for Immunotherapy.
Xu M; Lu JH; Zhong YZ; Jiang J; Shen YZ; Su JY; Lin SY
Front Oncol; 2022; 12():870914. PubMed ID: 35444934
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
Kwa MJ; Adams S
Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
[TBL] [Abstract][Full Text] [Related]
19. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.
Kim YA; Lee HJ; Heo SH; Park HS; Park SY; Bang W; Song IH; Park IA; Gong G
Breast Cancer Res Treat; 2016 Apr; 156(3):597-606. PubMed ID: 27075916
[TBL] [Abstract][Full Text] [Related]
20. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L
JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
